The data shows the ten most expensive Medicare Part B payments for cancer (and selected other) drugs delivered in the physician office and at home by total Medicare annual payments in 2014. During this time, annual Medicare payments for Denosumab injections totaled some 505.9 million USD. The size and demographic of medical professionals in oncology plays a significant role in the accessibility and quality of cancer care for patients in the U.S.
Ranibizumab injection | 1310.8 |
Aflibercept injection | 1239.9 |
Rituximab injection | 852.6 |
Infliximab injection | 785.9 |
Pegfilgrastim injection | 641.3 |
Bevacizumab injection | 594 |
Denosumab injection | 505.9 |
Trastuzumab injection | 289.3 |
Pemetrexed injection | 287.7 |
Bortezomib injection | 283 |